| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 68788-4133-03 | 68788-4133 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 11, 2026 | In Use | |
| 82249-0612-30 | 82249-0612 | Everolimus | Yulithira | 7.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 11, 2026 | In Use | |
| 82249-0613-30 | 82249-0613 | Everolimus | Yulithira | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 11, 2026 | In Use | |
| 68788-4133-01 | 68788-4133 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 11, 2026 | In Use | |
| 00310-9501-04 | 00310-9501 | Capivasertib | TRUQAP | 200.0 mg/1 | Chemotherapy | AKT Inhibitor | AKT1/2/3 | Oral | Jun 10, 2026 | In Use | |
| 00121-4882-94 | 00121-4882 | Ondansetron | Ondansetron | 4.0 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 9, 2026 | In Use | |
| 68788-4113-05 | 68788-4113 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jun 8, 2026 | In Use | |
| 68788-4113-06 | 68788-4113 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jun 8, 2026 | In Use | |
| 68788-4113-01 | 68788-4113 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jun 8, 2026 | In Use | |
| 68788-4113-03 | 68788-4113 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jun 8, 2026 | In Use | |
| 67046-1171-03 | 67046-1171 | PREDNISONE | Prednisone | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jun 5, 2026 | In Use | |
| 70121-2250-01 | 70121-2250 | ROMIDEPSIN | ROMIDEPSIN | 5.0 mg/mL | Chemotherapy | Enzyme Inhibitor | HDAC | Intravenous | Jun 2, 2026 | In Use | |
| 72603-0922-01 | 72603-0922 | DASATINIB | DASATINIB | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 1, 2026 | In Use | |
| 72603-0926-01 | 72603-0926 | DASATINIB | DASATINIB | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 1, 2026 | In Use | |
| 72603-0924-01 | 72603-0924 | DASATINIB | DASATINIB | 70.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 1, 2026 | In Use | |
| 72603-0927-01 | 72603-0927 | DASATINIB | DASATINIB | 140.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 1, 2026 | In Use | |
| 64842-0127-07 | 64842-0127 | FUTIBATINIB | LYTGOBI | 16.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR | Oral | Jun 1, 2026 | In Use | |
| 64842-0128-08 | 64842-0128 | FUTIBATINIB | LYTGOBI | 4.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR | Oral | Jun 1, 2026 | In Use | |
| 72603-0923-01 | 72603-0923 | DASATINIB | DASATINIB | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 1, 2026 | In Use | |
| 72603-0925-01 | 72603-0925 | DASATINIB | DASATINIB | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 1, 2026 | In Use | |
| 70518-2369-03 | 70518-2369 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | May 31, 2026 | In Use | ||
| 83831-0183-04 | 83831-0183 | Bendamustine hydrochloride | BENDAMUSTINE HYDROCHLORIDE | 100.0 mg/4mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | May 29, 2026 | In Use | |
| 83270-0451-05 | 83270-0451 | ETOPOSIDE | ETOPOSIDE | 50.0 mg/1 | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Oral | May 29, 2026 | In Use | |
| 70518-4669-00 | 70518-4669 | Dexamethasone | Dexamethasone | 0.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 27, 2026 | In Use | |
| 00074-0282-02 | 00074-0282 | Pivekimab sunirine-pvzy | DECNUPAZ | 2.0 mg/mL | Immunotherapy | Drug Antibody Conjugate | CD123 | Intravenous | May 27, 2026 | In Use |
Found 12611 results — Export these results
Home